Famous Patents
In 1608, Dutch eyeglass maker Hans Lipperhey filed the first patent for a working telescope. The patent was denied.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 5434073 | Fibrinolytic and anti-thrombotic cleavable dimers Relatively inactive fusion proteins are activatable by enzymes of the clotting cascade to have fibrinolytic and/or clot formation inhibition activity. For example, a fusion protein comprising two hirudin or streptokinase molecules, linked by a cleavable l... | 07/18/1995 |
| 5350578 | Inhibition of arterial thrombotic occlusion or thromboembolism The method of preventing arterial thrombotic occlusion or thromboembolism by administering plasma-derived or recombinant produced protein C alone or in combination with a thrombolytic agent or combinations of thrombolytic agents.... | 09/27/1994 |
| 5334384 | Process for purification of streptakinase using a reducing agent A process for the separation of streptokinase from contaminating proteins in a streptokinase-containing mixture, which comprises treating the mixture with a reducing agent to reduce disulphide bridges in the contaminating proteins to free thiol groups, co... | 08/02/1994 |
| 5308617 | Protein heparin conjugates A pharmaceutical composition is prepared wherein a biologically active conjugated protein is selectively conjugated to at least one heparin fragment having a terminal 2,5-anhydro-D-mannose residue which has an aldehyde not involved in intramolecular hemia... | 05/03/1994 |
| 5296366 | Method for the isolation and expression of a gene which codes for streptokinase, nucleotide sequence obtained, recombinant DNA and transformed microorgnaisms The present invention relates to the field of biotechnology and genetic engineering and in particular a novel nucleotide sequence which codes for a streptokinase, as well as the recombinant DNA obtained therefrom which is used for the transformation of va... | 03/22/1994 |
| 5272076 | Compounds and methods for treatment of thromboembolic disorders using an adduct of t-PA The present invention provides adducts of human t-PA derivatives, which comprise a t-PA derivative that lacks the Finger, Growth Factor and Kringle 1 domains, bound to an amphipathic molecule. The invention also provides methods for preparing the adducts ... | 12/21/1993 |
| 5256642 | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof The present invention relates to compositions comprising soluble complement receptor 1 (CR1) and a thrombolytic agent. In a specific embodiment, the thrombolytic agent is anisoylated human plasminogen-streptokinase activator complex (ASPAC). The invention... | 10/26/1993 |
| 5242688 | Method of treating thromboembolic disorders by administration of diglycosylated t-PA variants The present invention provides a method of treating thromboembolic disorders with the diglycosylated form of a tissue plasminogen activator derivative that lacks the Finger, EGF and Kringle I domains of the native tissue plasminogen activator molecule.... | 09/07/1993 |
| 5240845 | Mutated streptokinase proteins This invention relates to a novel chemically synthesized gene including a base sequence coding for the primary amino acid sequence of natutal-type streptokinase, a corresponding plasmid recombinant, corresponding transformant and process for preparing str... | 08/31/1993 |
| 5223408 | Method for making variant secreted proteins with altered properties A screening method for the selection of mutagenized proteins that are normally secreted by cells is described. The method includes the development of a cloning vector for the expression of secretory proteins as fusion proteins on the cell surface of trans... | 06/29/1993 |
| 5218137 | Light activated acyl-enzymes Light activated acyl-enzymes of the formula: ##STR1## are disclosed. In the compounds of Formula (III), ENZ is an enzyme, X is O or S, Y is --NR3 R4, --OR5, or --SR5, and Z is a nucleophile. m is 0 to 3 and... | 06/08/1993 |
| 5190756 | Methods and materials for expression of human plasminogen variant A cleavage-resistant plasminogen molecule is provided that is conveniently produced in recombinant cells by expression of a nucleic acid sequence encoding the plasminogen molecule. Preferably the plasminogen is a sequence variant with a modification in it... | 03/02/1993 |
| 5187098 | DNA encoding hybrid streptokinases with plasminogen fibrin binding domains Compositions and methods of the synthesis of hybrid streptokinase with fibrin binding domains based on gene fusion technology. Recombinant DNA methods have been used to fuse gene segments for streptokinase and for fibrin-binding domains and express the fu... | 02/16/1993 |
| 5116613 | Antibody-thrombolytic agent product and method of use A thrombolytic product comprising a fibrin-specific antibody substantially devoid of fibrinogen cross-reactivity coupled to a thrombolytic agent.... | 05/26/1992 |
| 5114851 | Light activated acyl-enzymes Light activated acyl-enzymes of the formula: ##STR1## are disclosed. In the compounds of Formula (III), ENZ is an enzyme, X is O or S, Y is --NR3 R4, --OR5, or --SR5, and Z is a nucleophile. m is 0 to 3 and... | 05/19/1992 |
| 5094950 | Diethylenetriamine pentaacetic acid derivatives A compound of the formula II: ##STR1## wherein n is an integer of 2 to 10, A' is a bivalent linking group formed by reacting both the reactive groups of a cross linking reagent, and B is a residue of a polypeptide compound, and physiologically acceptable ... | 03/10/1992 |
| 5084274 | Inhibition of arterial thrombotic occlusion or thromboembolism The method of preventing arterial thrombotic occulsion or thromboembolism by administering plasma-derived or recombinate produced protein C alone or in combination with a thrombolytic agent or combinations of thrombolytic agents.... | 01/28/1992 |
| 5068179 | Process for the determination of a component of an immune reaction in a plasma sample The present invention provides a method for the determination of a component of an immune reaction in a plasma sample using an immunoassay at a temperature of from 15° to 40° C., where one of the reactive components is in solid phase. The invention invo... | 11/26/1991 |
| 5066589 | Streptokinase-coding recombinant vectors A recombinant vector adapted for transformation of a suitable microorganism host to produce and secrete streptokinase. The recombinant vector comprises a plasmid into which a polydeoxyribonucleotide fragment from Streptococcus equisimilis H46A which codes... | 11/19/1991 |
| 5051264 | Potentiation of the thrombolytic effect of prourokinase type plasminogen activators by streptokinase The thrombolytic effect of known plasminogen activators such as tissue plasminogen activator (t-PA), prourokinase and modifications of t-PA and prourokinase is enhanced dramatically and unexpectedly when combined with streptokinase. The body is treated wi... | 09/24/1991 |
| 5015583 | Process for the purification of plasminogen activators (PA) A process is described for the purification of plasminogen activator (PA), wherein a solution containing such as plasminogen activator is brought into contact with a carrier-bound polysulfate of a saccharide or sulfated sugar, the liquid is removed, and t... | 05/14/1991 |
| 5011686 | Thrombus specific conjugates Disclosed is a method of targeting reagents to the locus of a clot, and a family of substances that have affinity for fibrin. The method and substances exploit the discovery that the binding sites on protein A from Staphylococcus aureus have a significant... | 04/30/1991 |
| 5004802 | 100KDa protein from blood which binds to and inhibits the activity of plasminogen activators A protein called PA binding protein has been isolated which binds specifically and reversibly to tissue plasminogen activator. The protein is characterized by a molecular mass of about 100,000 daltons, and electrophoretic mobility in agarose at pH 8.6 equ... | 04/02/1991 |
| 4889808 | Method of enchancing t-PA and SCU-PA production Disclosed herein is a method of enhancing the production of tissue plasminogen activator (t-PA) and single chain urokinase plasminogen activator (SCU-PA) by normal human lung diploid fibroblast cells in a serum-free medium. The method comprises the additi... | 12/26/1989 |
| 4820811 | Amine reacted therapeutic agents A complex of a therapeutic agent is disclosed in which the therapeutic agent is complexed to an ammonium ion selected from the group consisting of ##STR1## where R1 and R2 are the same or different and are alkyl or hydroxy ... | 04/11/1989 |
| 4808405 | P-anisoyl streptokinase/plasminogen complex A binary complex between streptokinase and plasminogen is prepared in which the catalytic site essential for fibrinolytic activity is blocked by a group which is removable by hydrolysis such that the pseudo-first order rate constant for hydrolysis of the ... | 02/28/1989 |
| 4764469 | Streptokinase-coding recombinant vectors A recombinant vector adapted for transformation of a suitable bacterial microorganism host to produce and secrete streptokinase. The recombinant vector comprises a plasmid into which a polydeoxyribonucleotide fragment from Streptococcus equisimilis H46A w... | 08/16/1988 |
| 4666697 | Radioactive diagnostic agent A radioactive diagnostic agent which comprises (1) a unit of a polyformyl compound having at least three formyl groups per molecule, (2) at least two units of an amino group-containing chelating compound bonded to the polyformyl compound a methyleneimine ... | 05/19/1987 |
| 4568544 | Aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration which comprises an aqueous medium and, dissolved therein, a high purity tissue plasminogen activator and at least one dissolution aid selected from the g... | 02/04/1986 |
| 4559221 | P-Glyoxyloylphenylalkanoic acid bis(thiosemicarbazone) derivatives, and their production and use A radioactive diagnostic agent which comprises a physiologically active substance and a radioactive metallic element combined with a compound of the formula: ##STR1## wherein R is a hydrogen atom or a C1 -C3 alkyl group and n is... | 12/17/1985 |
| 4552760 | Method for stabilizing tissue plasminogen activator and a stable aqueous solution or powder containing the same A method for stabilizing a tissue plasminogen activator which involves adding to an aqueous solution or powder containing a tissue plasminogen activator an effective amount of a purified gelatin is disclosed. A stable aqueous solution or powder which cont... | 11/12/1985 |
| 4507283 | Pharmacologically active compounds A derivative of streptokinase-human plasminogen activator complex, in which the active catalytic site essential for fibrinolytic activity is blocked by a 2- or 4-aminobenzoyl group, is useful in treating venous thrombosis. The blocking group is removable by hy... | 03/26/1985 |
| 4418052 | Diagnostic compositions and method for radiologic imaging of fibrinogen deposition in the body A novel injectable diagnostic composition comprises a fibrinolytic enzyme such as streptokinase-activated human plasmin or human urokinase, a stannous reducing agent and an alkaline sodium citrate reagent prepared and packaged as an instant non-radioactiv... | 11/29/1983 |
| 4378435 | Process for providing enzyme activity to a solid surface A process for providing enzyme activity to the surface of an article is described, comprising forming a film on the surface of the article, said film comprising an acid anhydride group-containing polymer and a polyol, wherein the acid anhydride groups are... | 03/29/1983 |
| 4315002 | Solid pharmaceutical or diagnostic agent containing dextran and its preparation A process for the preparation of a solid pharmaceutical or diagnostic composition in which the active substance and dextran are dissolved in water, the solution is placed in a mold and is thereafter lyophilized to form a solid abrasion-resistant tablet wh... | 02/09/1982 |
| 4285932 | Enzyme derivatives for use in the treatment of venous thrombosis A pharmaceutical composition which comprises a pharmaceutically acceptable carrier together with an in vivo fibrinolytic enzyme as defined herein wherein the catalytic site essential for fibrinolytic activity is blocked by a group which is removable by hy... | 08/25/1981 |
| 4082612 | Plasminogen activator complex A functionally active fraction of plasmin is provided which is capable of forming with streptokinase a complex with plasminogen activator activity. The fraction is made by reducing the disulfide bonds of plasmin molecules while inhibiting the serine protease a... | 04/04/1978 |
| 4011142 | Process for measuring the plasminogen content of a sample The plasminogen content of a blood sample is measured by determining the rate of formation of fibrin in a sample in which antiplasmin-free plasminogen is activated to form plasmin before the onset of fibrin formation so that the plasmin-conditioned break-... | 03/08/1977 |
